Clinical Trials Logo
  1. Home
  2. Allergic Contact Dermatitis
  3. NCT03945760

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

Allergic Contact Dermatitis Clinical Trial

Official title:
An Investigator Initiated Study to Evaluate the Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions In Healthy Adult Male Subjects

Clinical Trial Summary

The treatment of allergic contact dermatitis (ACD) can be unsatisfactory, and that other skin diseases such as atopic dermatitis have an increased likelihood of ACD, improved systemic treatments are needed. This research study explores the effectiveness of Baricitinib in treating Delayed-Type Hypersensitivity (allergic) versus Irritant Skin reactions. Subjects for this study need to be healthy males between the ages of 18 and 40. This study will evaluate this by injecting antigens as well as applying them on top of the skin to the forearm then measure the effects of Baricitinib by skin and blood testing.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03945760
Study type Interventional
Source Wright State Physicians
Contact
Status Completed
Phase Early Phase 1
Start date September 14, 2020
Completion date October 16, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05498467 - The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis Phase 3
Active, not recruiting NCT03680131 - Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis Phase 2
Recruiting NCT05535738 - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Phase 2/Phase 3
Recruiting NCT06191627 - Patient Experience and Quality of Patch Testing on the Legs vs Back N/A
Completed NCT00867607 - Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis Phase 1/Phase 2
Recruiting NCT00445029 - Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation N/A
Completed NCT04365140 - MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel
Recruiting NCT05991674 - A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques
Completed NCT00931242 - Study of Apremilast in Atopic or Contact Dermatitis Phase 2
Completed NCT01798589 - Bioequivalence of Ethylenediamine Dihydrochloride Study Phase 4
Completed NCT01546298 - Immune Reactions in Contact Dermatitis Affected Skin
Completed NCT05339750 - Allergy Skin Patch Artificial Intelligence (AI) N/A
Recruiting NCT03935971 - The Effects of Dupilumab on Allergic Contact Dermatitis Phase 4
Completed NCT01797562 - Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents N/A
Not yet recruiting NCT05858723 - Repeated Open Application Test (ROAT) Study With Hydroperoxides of Linalool N/A
Completed NCT02534441 - Epidemiology and Co-Reactivity of Novel Surfactant Allergens N/A
Not yet recruiting NCT01413477 - Nickel Desensitization Using Topical Therapy N/A
Completed NCT00133341 - Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate Phase 2
Completed NCT00132600 - Clinical Evaluation of Bacitracin Phase 2
Completed NCT03902392 - Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis N/A